Comparing the rectal Indomethacin plus oral coQ10 versus rectal indomethacin on prevention of post Endoscopic Retrograde Cholangio-pnacreatography pancreatitis

Effect of indomethacin suppository plus oral CoQ10 verusus indomethacin suppository in prevention of post Endoscopic Retrograde Cholangio-pnacreatography pancreatitis

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

IRCT

Registry ID

IRCT20121021011192N13

Enrollment

200

Registered

2022-09-28

Start date

2022-10-01

Completion date

Unknown

Last updated

2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatitis. K85.8

Interventions

Intervention 1: Intervention group: Administration of single dose of 100 mg rectal Indomethacine just before plus 200 mg CoQ10 tablet 2 hours before doing Endoscopic cholangiopancreatography. Interve

Eligibility

Sex/Gender

All

Age

20 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients undergoing ERCP in Taleghani hospital by taking written consent

Exclusion criteria

Exclusion criteria: Patients history of hypersensitivity against each of indomethacin or coQ10 History of sphinctrotomy

Design outcomes

Primary

Measure	Time frame
Pancreatitis. Timepoint: 10 days after doing Endoscopic Retrograde Cholangio-pancreatography. Method of measurement: clinical evaluation.	—

Secondary

Measure	Time frame
Gastrointestinal bleeding. Timepoint: 10 days after doing ERCP. Method of measurement: Clinical observation.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Abbasinazari

Shahid Beheshti University of Medical Sciences

m_abbasi@sbmu.ac.ir+98 21 8887 3704

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026